Motif Bio PLC (LON:MTFB, NASDAQ:MTFB) is expected to be able to chart a “path forward” for its lead drug iclaprim in the next month after a meeting with the US regulator went ahead as planned.
The company sought talks after the Food & Drug Administration declined to give the antibiotic the green light, citing in a document the need for additional data on liver toxicity.
As one of Motif’s advisers pointed out, this wasn’t a straight ‘no’.The firm has always said it was keen to discuss potential deficiencies with the information provided.
The latest meeting offered that chance, with feedback expected in the next 30 days.
“After Motif Bio has received the [FDA’s] minutes, the company will be in a position to provide an update to the market on the path forward for iclaprim,” the company said in a short investor update.
iclaprim is being developed as a treatment for acute skin infection.